Spring til hovednavigation Spring til søgning Spring til hovedindhold

Type IX Collagen Turnover Is Altered in Patients with Solid Tumors

  • Helena Port*
  • , Yi He
  • , Morten A. Karsdal
  • , Emilie A. Madsen
  • , Anne Christine Bay-Jensen
  • , Nicholas Willumsen
  • , Signe Holm Nielsen
  • *Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

20 Downloads (Pure)

Abstract

The fibrotic tumor microenvironment, characterized by its intricate extracellular matrix (ECM), consists of many collagens with diverse functions and unexplored biomarker potential. Type IX collagen is a member of the low-abundance collagen family known as the fibril-associated collagen with interrupted triple helices (FACITs) and is found mostly in cartilage. Its role in the tumor microenvironment remains unexplored. To investigate the biomarker potential of a type IX collagen in cancer, an immuno-assay was developed (PRO-C9) and technical assay performance was evaluated for the assessment of serum. PRO-C9 levels were measured in serum samples from 259 patients with various solid tumor types compared to serum levels from 73 healthy controls. PRO-C9 levels were significantly elevated in patients with solid tumors including bladder, breast, colorectal, gastric, head and neck, lung, melanoma, ovarian, pancreatic, and renal compared to levels in healthy controls (p < 0.05–p < 0.0001). PRO-C9 could discriminate between patients with cancer and healthy controls, with the area under the receiver operating characteristic values ranging from 0.58 to 0.86 (p < 0.3–p < 0.0001), indicating potential diagnostic utility. This study suggests that type IX collagen turnover is altered in patients with solid tumors and demonstrates the feasibility of using PRO-C9 as a non-invasive serum-based biomarker with relevance in multiple cancer types. Furthermore, these results underscore the potential utility of PRO-C9 to better elucidate the biology of FACITs in cancers.

OriginalsprogEngelsk
Artikelnummer2035
TidsskriftCancers
Vol/bind16
Udgave nummer11
Antal sider11
ISSN2072-6694
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
The present study was supported by Innovation Fund Denmark (0153-00086B) and the Danish Research Foundation.

Publisher Copyright:
© 2024 by the authors.

Finansiering

The present study was supported by Innovation Fund Denmark (0153-00086B) and the Danish Research Foundation.

Citationsformater